Iambic Therapeutics, Inc. (IAM)

Iambic Therapeutics will go public soon, but the exact IPO date is still unknown.

Stock Price: Pending

IPO price not available yet

Iambic Therapeutics Statistics

Total Valuation

Market Cap	n/a
Enterprise Value	n/a

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	n/a

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

Current Ratio	n/a
Quick Ratio	4.51
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	16.56

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	n/a
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	n/a
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	$106,731
Profits Per Employee	-$551,146
Employee Count	171
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

In the past 12 months, IAM has paid $47,000 in taxes.

Income Tax	47,000
Effective Tax Rate	n/a

Stock Price Statistics

Beta (5Y)	n/a
52-Week Price Change	n/a
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	n/a
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, IAM had revenue of $18.25 million and -$94.25 million in losses.

Revenue	18.25M
Gross Profit	18.25M
Operating Income	-100.19M
Pretax Income	-94.20M
Net Income	-94.25M
EBITDA	-98.87M
EBIT	-100.25M
Earnings Per Share (EPS)	n/a

Full Income Statement

Balance Sheet

The company has $207.88 million in cash and $5.08 million in debt, with a net cash position of $202.79 million.

Cash & Cash Equivalents	207.88M
Total Debt	5.08M
Net Cash	202.79M
Net Cash Per Share	n/a
Equity (Book Value)	-232.56M
Book Value Per Share	n/a
Working Capital	174.77M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$65.73 million and capital expenditures -$2.44 million, giving a free cash flow of -$68.17 million.

Operating Cash Flow	-65.73M
Capital Expenditures	-2.44M
Depreciation & Amortization	1.38M
Net Borrowing	n/a
Free Cash Flow	-68.17M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 100.00%, with operating and profit margins of -548.93% and -516.39%.

Gross Margin	100.00%
Operating Margin	-548.93%
Pretax Margin	-516.13%
Profit Margin	-516.39%
EBITDA Margin	-541.73%
EBIT Margin	-549.29%
FCF Margin	-373.50%

Dividends & Yields

IAM does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
FCF Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	n/a
FCF Yield	n/a

Analyst Forecast

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a
Revenue Growth Forecast (3Y)	n/a
EPS Growth Forecast (3Y)	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a